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Folinic acid is widely used in hematopoietic stem cell transplantation (SCT), mainly to reverse antifolate
effects of such drugs as methotrexate and cotrimoxazole but also empirically to reduce toxicity and support
hematopoietic recovery. However, concerns have been raised in oncohematology about reduced curative rates
associated with folinic acid administration. The clinical impact of folinic acid with regard to graft-versus-host
disease (GVHD), relapse, and rejection in pediatric SCT is largely undetermined. In this single-center retro-
spective study we investigated folinic acid administration in 87 children undergoing SCT between 2007 and
2010. Data on folinic acid dosage and duration were analyzed along with SCT parameters using univariate and
multivariate statistics. Folinic acid treatment was not correlated with relapse or GVHD grades  II. However,
signiﬁcantly higher folinic acid doses until day þ21 post-SCT had been administered to patients rejecting
their grafts (P < .005). In a subanalysis of nonmalignant disease and reduced-intensity conditioning
(RIC) SCTs, higher total folinic acid doses were found to be associated with rejection (P ¼ .015 and P ¼ .026).
Multivariate analysis identiﬁed RIC (odds ratio, 19.9; P < .01) and an early total folinic acid dose
of >185 mg/m2 (odds ratio, 11.4; P ¼ .03) as risk factors for graft rejection. Late folinic acid treatment had no
impact on relapse, GVHD, and rejection. To conclude, administration of folinic acid in pediatric SCT seems safe
in terms of relapse and GVHD. However, it should be carried out with caution, especially in patients with
nonmalignant conditions and those receiving RIC to avoid graft rejection.
 2013 American Society for Blood and Marrow Transplantation.INTRODUCTION
Folinic acid is widely used to minimize the side effects of
antifolate chemotherapeutic agents administered to patients
suffering from hematologic and oncologic disorders. In
allogeneic hematopoietic stem cell transplantation (SCT),
folinic acid is used to reduce the toxicity associated with
graft-versus-host disease (GVHD) prophylaxis with metho-
trexate (MTX) [1,2] and, ex juvantibus, to minimize side
effects of the conditioning regimen. The beneﬁcial effect of
folinic acid administration in SCT (ie, reduced toxicity but
preserved anti-GVHD effects of MTX) was demonstrated in
dogs during the late 1970s [3,4]. Subsequently, the role of
folinic acid in attenuating MTX-related side effects has been
conﬁrmed in clinical studies, also in non-SCT patients [2,5,6].
However, over several years it has been debated whether
administration of folinic acid is necessary in SCT and if it
might reduce the curative rate for hematologic malignancies
by selectively rescuing leukemic cells [7-9]. The reduced
antileukemic effect was also illustrated by Skäreby et al. [10],
who described an increased risk of relapse in childrenedgments on page 328.
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treatment in the NOPHO 92 ALL protocol. In addition to
administration of folinic acid as part of the conditioning
regimen and on the following days, some cytopenic children
have been given folinic acid post-SCT to reduce antifolinic
acid effects by cotrimoxazole and to support hematopoietic
recovery [1,11]. Because there are conﬂicting data concerning
beneﬁts and potential hazards associated with folinic acid,
the aim of this study was to investigate the correlation
between folinic acid treatment and graft rejection, relapse,
and GVHD in children undergoing SCT.METHODS
Patients
Between 2007 and 2010, 75 pediatric patients underwent SCT at our
center. A number of patients underwent more than one SCT, with 87 total
performed SCTs. Most patients had hematologic malignancies, but patients
with nonmalignant conditions (ie, benign hematologic, metabolic, and
primary immunodeﬁciency disorders) were also included (Table 1). The
study was approved by the Regional Ethical Review Board in Stockholm.SCT Procedure
The SCT procedure and conditioning regimens have been published
previously [12], and treatment data are presented in Table 1. In most SCTs
cyclosporine A and MTX (n ¼ 52, 59.8%) were used as prophylaxis against
GVHD. In the remaining SCTs, cyclosporine A and prednisolone (n ¼ 16,
18.4%), tacrolimus and sirolimus (n ¼ 13, 14.9%), or other combinations
(n ¼ 6, 6.9%) were administered. Antithymocyte globulin was applied when
the stem cell source was an unrelated donor or in certain cases (n ¼ 69,
79.3%). Cotrimoxazolewas used as Pneumocystis jiroveci prophylaxis, in most
cases 3 days per week during the ﬁrst 6 months post-SCT.
Table 1
Patient Characteristics (SCT, n ¼ 87)
Characteristic Value
Age, yr 7 (.25-19)
Sex, M/F 62 (71.3%)/25 (28.7%)
Diagnosis
Nonmalignant 39 (44.8%)
Acute leukemia 29 (33.3%)
MDS 15 (17.2%)
Other malignancy 4 (4.6%)
Stage, early/late 53 (60.9%)/34 (39.1%)
Donor
HLA-identical related 27 (31.0%)
MUD 41 (47.1%)
Mismatched* 19 (21.8%)
GVHD prophylaxis
CsA þ MTX 52 (59.8%)
CsA þ prednisolone 16 (18.4%)
Tacrolimus þ sirolimus 13 (14.9%)
Other 6 (6.9%)
Conditioning
Cyclophosphamide 1 (1.1%)
fTBI þ cyclophosphamide 20 (23.0%)
Busulphan þ cyclophosphamide 31 (35.6%)
Fludarabine þ cyclophosphamide 9 (10.3%)
Fludarabine þ fTBI þ cyclophosphamide 3 (3.4%)
Fludarabine þ treosulphan 23 (26.4)
Antithymocyte globulin 69 (79.3%)
Nucleated cell dose, 108/kg (range) 4.9 (.2-34)
CD34 dose, 106/kg (range) 4.3 (.03-28.2)
Stem cell source
BM/PBSC/CB 56 (64.4%)/13 (14.9%)/
18 (20.7%)
Donor sex, M/F 51 (58.6%)/36 (41.4%)
Donor age, yr (range) 21 (0-52)
Acute GVHD
0 43 (49.4%)
I 9 (10.3%)
II 25 (28.7%)
III-IV 10 (11.5%)
Relapse, yes/no 10 (20.8%)/38 (79.2%)
Rejection 11 (12.6%)
Retransplant
First SCT 73 (83.9%)
Second SCT 12 (13.8%)
Third SCT 2 (2.3%)
MDS indicates myelodysplastic syndrome; HLA, human leukocyte antigen;
MUD, HLA-A, -B, and -DR matched unrelated donor; CsA, cyclosporine; fTBI,
fractionated total body irradiation; BM, bone marrow; PBSC, peripheral
blood stem cells; CB, cord blood.
* HLA-A, -B or -DR mismatched unrelated donor.
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Patients receiving GVHD prophylaxis containing MTX on
days þ1, þ3, þ6, and þ11 were given approximately 10 mg/m2 folinic acid
either daily from day 1 or day 1, þ2, þ4, þ7, þ8, þ9, þ12 and thereafter
daily until an absolute neutrophil count >.5  109/L was found. In patients
not receiving MTX, folinic acid in a similar dose and course was adminis-
tered along with the conditioning regimen ex juvantibus on clinical indi-
cation to reduce toxicity and support hematopoietic recovery. Furthermore,
folinic acid was also administered in some cytopenic patients at a later stage
to reverse antifolic effects of cotrimoxazole and to support hematopoietic
recovery. Folinic acid administration along with the conditioning regimen
(ie, starting on day 1 to þ14) or at a later stage (ie, day þ15 and beyond) is
referred to here as early and late folinic acid treatment, respectively.
Data Collection
Data on each patient were obtained from medical records and patient
databases. The collected data included basic parameters (eg, height, weight,
age, and sex), transplant characteristics (eg, diagnosis, conditioning, GVHD
prophylaxis, donor source, and cell dose), and outcome parameters
(eg, rejection, relapse, and GVHD reactions). Data on MTX, cotrimoxazole,
and folinic acid dosage (eg, average daily dose, total dose) and treatment
time were extracted from medication administration records. To verify the
reproducibility of the abstracted data, 10 patients were selected randomly
and reabstracted. Complete agreement between the two abstractions was
conﬁrmed.Outcome Data
The endpoints chosen were GVHD, relapse, and rejection. Acute GVHD
was graded following the international standard 1-4 [13]. Relapse was
deﬁned as increasing minimal residual disease, reaching diagnostic criteria.
Rejection was deﬁned as progressive mixed chimerism reaching >90%
recipient-derived cells in the lineage of interest. GVHD, relapse, rejection,
and survival data were locked for analysis on December 31, 2011.Statistics
Relapse and GVHD were estimated using an estimator of cumulative
incidence curves, taking competing events into consideration [14,15]. The
logistic regression method was used in the predictive analysis for rejection.
Factors analyzed were folinic acid dose and duration, age, diagnosis, donor,
GVHD prophylaxis, nucleated cell dose, conditioning regimen, antithymo-
cyte globulin, and stem cell source. Continuous variables were compared
using the Mann-Whitney or Kruskal-Wallis test. Statistical signiﬁcance was
set at P < .05.RESULTS
Folinic acid was administered early in 71 SCTs (81.6%),
both early and late in 15 (17.2%) and only late in 1 (1.1%). The
median treatment durations were 22 (range, 5 to 115) and
105 (range, 58 to 131) days for the early and late treatment
stages, respectively. The total median folinic acid treatment
dose per m2 was 190 mg (range, 59.5 to 1111.8) for early
treatment and 979 mg (range, 158.5 to 2194.5) for late
treatment, whereas the average daily doses per m2 were
10.7 mg (range, 8 to 35.8) and 13.8 mg (range, 5.3 to 24.1),
respectively. In 30 SCTs (34%) folinic acid treatment was
given without prior MTX administration.Rejection
The total doses of early folinic acid associated with the
risk of graft rejection in the analysis of all patients (median
[range]) for rejection versus nonrejection were 241 [127-
500] and 178 [31-1112] mg/m2 (P < .01), whereas the daily
average dose (median 10.5 [8.4-35.8] versus 10.3 [8.0-27.6]
mg/m2) and duration (median 23 [18-32] versus 21 [5-114]
days) had no correlation with graft rejection. These ﬁnd-
ings remained unaltered when adjusted for MTX dosage
(ie, MTX/CAL ratio > 1.0 versus <1.0).
To control for the possibility that clinicians increased
folinic acid treatment due toworries about graft rejection, an
analysis of the total folinic acid dose until day þ21 post-SCT
was performed. The correlation between a higher folinic acid
dose and rejection was still conﬁrmed (median 207 [127-
442] versus 165 [0-301] mg/m2, P ¼ .005, Figure 1A).
Because rejections are reported more frequently in nonma-
lignant and reduced-intensity conditioning (RIC) SCTs,
further analyses were performed. A higher total dose until
dayþ21 was seen in rejections compared with nonrejections
among patients with nonmalignant diseases (median 210
[127-442] versus 186 [0-301] mg/m2, P ¼ .015, Figure 1B) as
well as in patients with RIC (median 210 [127-442] versus
180 [62-301] mg/m2, P ¼ .026, Figure 1C).
Correlations between early total folinic acid dose and
SCT parameters associated with graft rejection were identi-
ﬁed: engraftment (ie, days to absolute neutrophil
count >.5  109/L, r ¼ .59, P < .001), total nucleated cell dose
(r ¼ .21, P ¼ .005), and CD34þ cell dose (r ¼ .36, P ¼ .001).
However, in a further multivariate analysis, only RIC (odds
ratio, 19.9; 95% conﬁdence interval, 2.22 to 177, P < .01) and
an early total folinic acid dose >185 mg/m2 (odds ratio, 11.4;
95% conﬁdence interval, 1.24 to 104, P ¼ .03) were identiﬁed
as risk factors for graft rejection. The characteristics of
patients with graft rejection are presented in Table 2.
Figure 1. Folinic acid supplementation is associated with graft rejection.
A higher total folinic acid dose until day þ21 post-SCT was observed in
the SCTs where graft rejection occurred (A). The correlation was also
conﬁrmed in patients with nonmalignant diseases (B) and reduced-intensity
conditioning (C).
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Total dose, daily mean dose, and duration of early folinic
acid treatment had no correlation with relapse in malignant
disease. No impact of folinic acid treatment on relapse could
be identiﬁed when adjusted for the MTX dosage (ie, MTX/
CAL ratio > 1.0 versus <1.0). Late folinic acid was not asso-
ciated with an increased incidence of relapse.
GVHD
Total dose, daily mean dose, and duration of early folinic
acid treatment had no correlation with the frequency of
acute GVHD grade I, II, or III-IV. No effect of folinic acid
treatment on GVHD could be identiﬁed on adjusting for MTX
dosage (ie, MTX/CAL ratio> 1.0 versus< 1.0). Late folinic acidtreatment was not found to be associated with an increased
incidence of GVHD.
DISCUSSION
Folinic acid reduces mucosal and gastrointestinal side
effects caused by MTX [1,2,6]. Moreover, folinic acid is
sometimes used in a situation of poor hematopoietic
recovery in hematologic patients, despite insufﬁcient sup-
porting data and, over the years, even contradictory research
evidence [8,16]. However, reports raising concerns that
folinic acid selectively rescues malignant cells have led some
clinicians to restrict folinic acid usage [8-10].
The present study found no association between folinic
acid dosage or treatment duration and relapse in malignant
disease in either early or late administration. The same
patternwas also seenwhen correlatedwith the administered
MTX dose. The interpretation of the present data is that
folinic acid might be used in pediatric patients undergoing
SCTs due to malignant disease. The concerns about an
increased relapse risk as a result of folinic acid rescue of
malignant cells [9,10] do not seem to be valid in pediatric SCT
patients who have received high-dose chemotherapy to
achieve acceptable pre-SCT minimal residual disease and
heavy SCT conditioning.
If folic acid rescued malignant cells and supported
lymphocyte proliferation [8,17], one may hypothesize that
donor-derived lymphocytes that mediate GVHD could
beneﬁt from the same supporting effect. Nevertheless, no
association was found between folinic acid dosage and
treatment duration and GVHD, after either early or late
administration or when correlated with the administered
MTX dose.
Patients rejecting their grafts, however, had received
signiﬁcantly higher early folinic acid doses (ie, starting at
day 1 to þ14) compared with patients without graft
rejection. In the absence of engraftment or suspicion of
threatening graft failure, folinic acid supplementation is
easily continued, although its efﬁcacy is noneevidence based
to support hematopoietic recovery. To control for this
possible confounder, we compared total doses until day þ21
post-SCT, and the correlation between rejection and dose
remained valid. Virtually all rejections occurred after SCTs for
nonmalignant diseases and RIC SCTs, but also within these
groups there was a correlation with the folinic acid doses.
Obviously, these patients received less aggressive condi-
tioning with the risk of leaving residual recipient marrow
cells [18,19]. In an analogy with leukemic cells being rescued
by folinic acid and lymphocytes promoted to proliferate
[8,17], one can hypothesize that the residual recipient
marrow cells might have a better chance to survive due to
folinic rescue, with subsequent rejection as a result. This
hypothesis of restored host immunity is supported by others
describing beneﬁcial effect of folinic acid on immune func-
tion, already at levels far inferior to those used in SCT [17,20].
It might also be assumed that folinic acid rescue can be even
more pronounced in patients receiving low-dose or no MTX.
Additionally, the known polymorphisms in the inter-
connected metabolic pathways of folinic acid should be
taken into consideration. The administration of the same
dose folinic acid to different patients may result in varying
serum levels, with a possible subsequent effect on graft
survival [21].
To summarize, the present study indicates that folinic
acid is safe in pediatric SCT with regard to relapse in malig-
nant disease and GVHD. However, the study suggests that
Table 2
Characteristics of Patients with Graft Rejection
UPN Sex Age (yr) Diagnosis Donor Conditioning GVHD Prophylaxis CD34þ
Dose
(106/kg)
Day
ANC > .5  109/L
Day of
Rejection
Total Early
Folic Acid
Dose (mg/m2)
1231 M 8 Fanconi MUD FLUþCYþATG CyA þ prednisolone .8 d þ25 332.9
1238a M 1 Hurler MUD FLUþTREOþATG Tacrolimus þ
sirolimus
5.6 þ20 þ68 441.5
1238b M 2 Hurler MUD FLUþCYþATG CyA 6.6 þ19 þ61 127.0
1230a F 2 Kostman SIB FLUþTREOþATG CyA þ prednisolone .6 þ54 þ107 188.7
1269a M 18 Kostman SIB FLUþTREOþATG CyA þ MTX 1.0 þ23 þ49 241.5
1318b M 11 CGD MUD FLUþCYþATG CyA þ prednisolone .1 þ19 þ34 190.5
1360a M 1 SCID MUD FLUþTREOþATG CyA þ prednisolone .04 þ25 þ79 412.4
1390a M 3 CGD MUD FLUþTREOþATG tacrolimus þ
sirolimus
4.3 þ21 þ80 203.9
1396b M .5 SCID MUD FLUþTREOþATG CyA þ prednisolone .14 þ30 þ25 406.5
1396a M .25 SCID Mother ATG CyA þ MTX þ TcD 6.3 d þ28 500.0
1421a M 4 JMML MUD BUþCYþATG CyA þ MTX 5.9 þ27 þ48 185.8
UPN indicates unique patient number; ANC, absolute neutrophil granulocyte count; a, ﬁrst SCT; b, second SCT; CGD, chronic granulomatous disease; SCID, severe
combined immunodeﬁciency; JMML, juvenile myelomonocytic leukemia; MUD, HLA-matched unrelated donor; SIB, HLA-identical sibling donor; FLU, ﬂudar-
abine; CY, cyclophosphamide; ATG, antithymocyte globulin; TREO, treosulphan; CyA, cyclosporine A; MTX, methotrexate; TcD, T-lymphocyte depletion.
H. Lindqvist et al. / Biol Blood Marrow Transplant 19 (2013) 321e332328administration of folinic acid should be limited and conser-
vative in pediatric patients with nonmalignant conditions
and those receiving RIC. Folinic acid should probably be
avoided in patients with adequate folate levels in cases
where MTX is omitted from the conditioning. Further
studies, clinical as well as laboratory based, investigating the
role of folinic acid in SCT biology are warranted.
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